Today: 3 July 2026
Browse Category

NSE:AGEL 29 October 2025

Adani Green Profit Surge Triggers Stock Rally – Analysts See More Upside Ahead

Adani Green Profit Surge Triggers Stock Rally – Analysts See More Upside Ahead

India’s renewable energy bellwether Adani Green delivered a solid quarterly performance. Net profit jumped about 25% year-on-year to ₹644 crore in Q2 FY26, up from ₹515 crore a year agohindustantimes.com. This surge came despite total income being largely flat – revenue from operations was ₹3,008 crore versus ₹3,005 crore in Q2 last yearhindustantimes.com. The top-line was steady, but the quality of revenue improved: income from the core power supply business rose 20% to ₹2,776 crorebusinesstoday.in, supported by new capacity additions and higher utilization of renewable plants. The company’s EBITDA from power supply grew 19% as well, reflecting healthy marginsbusiness-standard.com. According to an exchange filing, robust greenfield capacity additions and improved performance at new plants in resource-rich sites like Khavda and Rajasthan drove the growth in revenue and earningsbusinesstoday.in. While operational revenue grew, total quarterly income actually dipped ~4% to ₹3,249 croremoneycontrol.com, possibly due to lower other income. Still, profitability improved markedly. Adani Green’s management noted that cash profit rose 8% YoY to ₹1,349 croremoneycontrol.com, indicating stronger cash generation. Notably, the firm’s solar and wind plants saw high utilization – the solar portfolio’s capacity utilization factor stood at 24.8% and wind at 37.8%, which the company considers robustreuters.com. Overall, the quarter’s

Stock Market Today

  • Mesoblast (ASX:MSB) gains 9.3% as FDA accepts modular review of Rexlemestrocel-L BLA
    July 3, 2026, 1:10 PM EDT. Shares of Mesoblast (ASX:MSB) rose 9.3% after the FDA agreed to review its Biologics License Application for rexlemestrocel-L. The therapy, aimed at stopping gastrointestinal bleeding in end-stage heart failure patients on LVADs, will follow a modular review process under FDA's flexible pathway for rare, high-mortality diseases. Mesoblast landed US$50 million in new funding recently, giving it more time to run late-stage trials. The company is still counting on trial results and regulatory progress before it can turn a profit. Analysts see possible revenue of A$485.4 million and earnings of A$222.1 million by 2029, but say there's still plenty of risk.
Go toTop